Login
$PEPG
$4.19 +$0.00 (0.0%) After hours

Company Executives

Officer Age In this role 2025 pay Source
James McArthur Also a director
President and CEO
Title from the Form 4 dated Mar 4, 2026
64 Not stated $3,316,783
Noel P. Donnelly
Chief Financial Officer
56 Since 2021
5 years
$1,758,882
Joseph D. Vittiglio
Chief Business & Legal Officer and Secretary
54 Not stated $1,319,816
Kasra Kasraian
Chief Technical Officer
59 Since 2025
1 year
Not reported
Paul Streck
Executive Vice President, Head of Research & Development
63 Since 2024
2 years
Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
8
serving now
Independent
7 of 8
stated in the proxy
Average tenure
3.9 years
from year joined
CEO also chairs the board
No
Laurie B. Keating
Director Age On board Independent Committees Other public boards 2025 pay Source
Laurie B. Keating
72 2021
5 years
Independent
Audit Committee Nominating and Corporate Governance Committee
Immuneering Corporation (Nasdaq: IMRX) $102,398
James McArthur
64 2021
5 years
Not independent None stated None stated Paid as CEO
Howard Mayer
63 2023
3 years
Independent
Compensation Committee · Chair
None stated $70,898
Joshua Resnick
51 2020
6 years
Independent
Nominating and Corporate Governance Committee
Sionna Therapeutics, Inc. (Nasdaq: SION) $64,398
Lisa Wyman
48 2025
1 year
Independent
Nominating and Corporate Governance Committee
NewAge Industries, Inc. $64,006
Habib Joseph Dable
56 2022
4 years
Independent
Audit Committee
Relay Therapeutics (Nasdaq: RLAY), Tyra Biosciences, Inc (Nasdaq: TYRA) $71,898
Mitchell H. Finer
67 2025
1 year
Independent
Compensation Committee
None stated Not stated
Heidi Henson
60 2020
6 years
Independent
Audit Committee · Chair Compensation Committee
Lisata Therapeutics, Inc. (Nasdaq: LSTA), Perspective Therapeutics, Inc. (NYSE: CATX) $78,398

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

No related-party transactions disclosed

The proxy filed Apr 28, 2026 describes a review policy but reports no transactions.

Read the policy in the proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support